RS63302B1 - Upotreba dopaminskih d3 delimičnih agonista za tretiranje poremećaja centralnog nervnog sistema - Google Patents

Upotreba dopaminskih d3 delimičnih agonista za tretiranje poremećaja centralnog nervnog sistema

Info

Publication number
RS63302B1
RS63302B1 RS20220566A RSP20220566A RS63302B1 RS 63302 B1 RS63302 B1 RS 63302B1 RS 20220566 A RS20220566 A RS 20220566A RS P20220566 A RSP20220566 A RS P20220566A RS 63302 B1 RS63302 B1 RS 63302B1
Authority
RS
Serbia
Prior art keywords
dopamine
receptor
agonist
rls
compound
Prior art date
Application number
RS20220566A
Other languages
English (en)
Serbian (sr)
Inventor
Jeanne-Marie Lecomte
Jean Charles Schwartz
Isabelle Berrebi-Bertrand
Stéphane Krief
Xavier Ligneau
Original Assignee
Bioprojet Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Pharma filed Critical Bioprojet Pharma
Publication of RS63302B1 publication Critical patent/RS63302B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20220566A 2020-05-04 2020-05-04 Upotreba dopaminskih d3 delimičnih agonista za tretiranje poremećaja centralnog nervnog sistema RS63302B1 (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20305429.1A EP3906927B1 (en) 2020-05-04 2020-05-04 Use of dopamine d3 partial agonists for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
RS63302B1 true RS63302B1 (sr) 2022-07-29

Family

ID=70802820

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220566A RS63302B1 (sr) 2020-05-04 2020-05-04 Upotreba dopaminskih d3 delimičnih agonista za tretiranje poremećaja centralnog nervnog sistema

Country Status (23)

Country Link
US (1) US12582648B2 (es)
EP (2) EP3906927B1 (es)
JP (2) JP2023523862A (es)
KR (1) KR20230005860A (es)
CN (1) CN115715195A (es)
AU (1) AU2021267681A1 (es)
BR (1) BR112022022317A2 (es)
CA (1) CA3176643A1 (es)
CY (1) CY1125228T1 (es)
DK (1) DK3906927T3 (es)
ES (1) ES2925982T3 (es)
HR (1) HRP20220739T1 (es)
HU (1) HUE059092T2 (es)
IL (1) IL297706A (es)
LT (1) LT3906927T (es)
PL (1) PL3906927T3 (es)
PT (1) PT3906927T (es)
RS (1) RS63302B1 (es)
SI (1) SI3906927T1 (es)
SM (1) SMT202200332T1 (es)
UA (1) UA130345C2 (es)
WO (1) WO2021224235A1 (es)
ZA (1) ZA202211589B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535386A (zh) * 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 腸溶包衣必托里賽（ｐｉｔｏｌｉｓａｎｔ）調配物及使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
EA005002B1 (ru) * 1999-12-10 2004-10-28 Уайт НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
EP1591455A1 (en) 2004-04-29 2005-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Essential tremor diagnostic and treatment
WO2007113260A1 (en) 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
AU2007233715A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
KR20180021693A (ko) * 2015-05-07 2018-03-05 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환을 치료하는 조성물 및 방법

Also Published As

Publication number Publication date
AU2021267681A1 (en) 2022-12-01
DK3906927T3 (da) 2022-06-20
HRP20220739T1 (hr) 2022-08-19
HUE059092T2 (hu) 2022-10-28
SMT202200332T1 (it) 2022-09-14
CA3176643A1 (en) 2021-11-11
CN115715195A (zh) 2023-02-24
SI3906927T1 (sl) 2022-08-31
PL3906927T3 (pl) 2022-07-25
KR20230005860A (ko) 2023-01-10
LT3906927T (lt) 2022-08-10
IL297706A (en) 2022-12-01
JP2025120504A (ja) 2025-08-15
EP3906927B1 (en) 2022-05-25
PT3906927T (pt) 2022-07-27
CY1125228T1 (el) 2025-03-28
ES2925982T3 (es) 2022-10-20
EP3906927A1 (en) 2021-11-10
EP4146214A1 (en) 2023-03-15
JP2023523862A (ja) 2023-06-07
BR112022022317A2 (pt) 2022-12-13
WO2021224235A1 (en) 2021-11-11
ZA202211589B (en) 2023-04-26
US12582648B2 (en) 2026-03-24
US20230165852A1 (en) 2023-06-01
UA130345C2 (uk) 2026-01-28

Similar Documents

Publication Publication Date Title
CN103108633B (zh) TrkB激动剂及其用途
WO2008036410A2 (en) Methods and compositions for treating amyotrophic lateral sclerosis (als)
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
JP6574769B2 (ja) 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
KR20140113689A (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
JP2021507889A (ja) ピラゾロピペリジン誘導体の新規な使用
JP2006077034A (ja) Ｎｍｄａ受容体媒介性神経障害の防止薬剤
US20110124683A1 (en) Use of CRTH2 Antagonist Compounds
CZ20032338A3 (cs) Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch
JP2013533310A (ja) 苦味物質を使用して閉塞性肺疾患を処置する方法
US9505727B2 (en) Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels
KR20200061310A (ko) 히스톤 탈아세틸화효소 6 억제제를 포함하는 약학적 조성물
HK1247847A1 (zh) 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
JP2025120504A (ja) 中枢神経系障害を治療するためのドーパミンｄ３部分アゴニストの使用
AU2025279746A1 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP6232547B2 (ja) 聴覚障害又は小脳性運動失調症の予防・治療剤
JP7569522B2 (ja) 運動ニューロン疾患の予防剤及び／又は治療剤
EA049660B1 (ru) Применение частичных агонистов дофамина d3 для лечения заболеваний центральной нервной системы
CN105592849A (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
Kawabe et al. Effects of early postnatal MK-801 treatment on behavioral properties in rats: differences according to treatment schedule
WO2025092882A1 (en) COMBINATION OF A NORADRENERGIC α2A RECEPTOR AGONIST AND A NOREPINEPHRINE DOPAMINE REUPTAKE INHIBITOR AND USE THEREOF
JP2025502526A (ja) てんかんにおける突然の予期せぬ死に関連する疾患を治療するためのセロトニン５－ｈｔ１ａ受容体アゴニストの使用
ES2869887T3 (es) Agonistas de blt2 para el tratamiento del dolor
WO2025052177A2 (en) Novel composition and methods of treating a neurodegenerative disease
WO2023049482A1 (en) Methods of treating restrictive eating disorders